Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    PNC-27

    OtherPreclinical

    Also known as: PNC-27 peptide, p53-HDM2 inhibitor peptide, anti-cancer peptide

    PNC-27 is a p53-derived peptide that selectively induces membranolysis in cancer cells. It contains the p53 transactivation domain (amino acids 17–26) linked to a membrane-penetrating transmembrane domain (HDM2 binding domain).

    Price check

    Out of stock right now

    None of the vendors we track has it in stock.

    Half-life: Unknown (no published PK data)Route: Subcutaneous, Intravenous, IntraperitonealMW: 4031.8 g/mol (average)
    Last reviewed:

    Overview

    At A Glance

    Mechanism

    PNC-27 is a 32-amino-acid chimeric peptide that fuses the HDM-2 (MDM2)-binding domain of p53 - residues 12-26 (PPLSQETFSDLWKLL) - to a C-terminal membrane-residency / penetratin-derived leader sequence. Cancer cells aberrantly express HDM-2 protein on their plasma-membrane surfac…

    Half-Life
    Unknown (no published PK data)
    Dosing
    variable
    Routes
    SubcutaneousIntravenousIntraperitoneal
    Common Vials
    10mg
    Potential Benefits
    Selective cancer cell membranolysis via surface-expressed HDM2 targetingIn vitro activity against pancreatic cancer, leukemia, breast cancer, and melanoma cellsSpares normal cells — no HDM2 surface expression on non-malignant tissueRapid cytotoxic action — membranolysis within minutes of contact in vitroResearch model for non-apoptotic cancer cell killing mechanisms
    Safety Notes
    Common
    No human safety data existsIn vitro toxicity against cancer cells only
    Serious
    No clinical safety data available — strictly preclinical compoundUnknown off-target effects at therapeutic concentrations in vivoDo NOT use as self-treatment

    Overview

    PNC-27 is a p53-derived peptide that selectively induces membranolysis in cancer cells. It contains the p53 transactivation domain (amino acids 17–26) linked to a membrane-penetrating transmembrane domain (HDM2 binding domain). Uniquely, PNC-27 kills cancer cells by binding to HDM2 protein on the cancer cell membrane surface — where HDM2 (the p53 negative regulator) is aberrantly expressed — creating pores in the cancer cell plasma membrane. Normal cells, which do not express surface HDM2, are spared. This selectivity distinguishes PNC-27 from most cytotoxic compounds. Published research comes primarily from Sarafraz-Yazdi et al. and has demonstrated selective pancreatic cancer, leukemia, and breast cancer cell kill in vitro. PNC-27 remains preclinical with no clinical trials completed.

    Chemical Information

    IUPAC Name

    Not yet available

    CAS Number

    Not yet available

    Molecular Formula

    Not yet available

    Molecular Mass

    4031.8 g/mol

    Amino Acid Sequence

    Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly (PPLSQETFSDLWKLLKKWKMRRNQFWVKVQRG); 32-amino-acid chimeric peptide - p53 HDM-2-binding domain residues 12-26 (PPLSQETFSDLWKLL) fused to a C-terminal membrane-residency / penetratin-derived leader sequence (KKWKMRRNQFWVKVQRG).

    Dosing & Protocols

    Unlock the Dosing tab

    Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

    • Route and how often
    • Common vial sizes

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    Research

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

    • A summary of the key research
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    Interactions

    Interaction and contraindication data is being compiled for PNC-27. Check back soon.

    General Safety Note

    Always consult a qualified healthcare professional before combining research compounds. Interactions may exist that are not yet documented.

    Best Price

    $119.00

    Best $/mg

    $11.9000

    Vendors

    1

    Listings

    1

    vial

    Form
    Sort
    Vendor Product Form Qty Price $/mg Coupon
    Ion Peptide logo
    Ion Peptide
    70
    🇺🇸US🌍International
    PNC-27 10mg vial 1 vial● Out of Stock $119.00BEST $11.90 —

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with PNC-27.

    Current low
    $119.00
    current listings
    7-day low
    —
    not enough history yet
    30-day low
    —
    not enough history yet
    30-day change
    —
    not enough history yet

    Tracking since Apr 22, 2026 · 1 data point

    Vendors Selling PNC-27

    How we score these vendors

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.

    View Scorecard

    Related Compounds

    View All

    Aminotadalafil

    OtherPreclinical

    Aminotadalafil is an unapproved research analog of tadalafil, the PDE5 inhibitor marketed under the brand name Cialis for erectile dysfunction and under Adcirca for pulmonary arterial hypertension.

    2.5 mg - 20 mg (oral)
    9 PubMedView Profile

    B7-33

    OtherPreclinical

    B7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.

    t½ In vitro serum-stability half-life is approximately 6 minutes; B7-33 is rapidly degraded (a lipidated analog extended this to ~60 minutes in the same assay). Human in vivo pharmacokinetics are unpublished, and rapid clearance is expected for a small linear peptide (Praveen et al. 2023, PMID 37047588). 500-4000 mcg subcutaneous per injection (community/self-report research doses; most commonly ~1000 mcg / 1 mg once daily). No validated human dose exists - all figures are empirical extrapolations from rodent pharmacology.
    11 PubMedView Profile

    Diisopropylamine dichloroacetate (DADA)

    OtherApproved (Japan)

    DADA is the abbreviation the research chemical market uses for diisopropylamine dichloroacetate, the diisopropylamine salt of dichloroacetic acid, CAS 660-27-5.

    PreclinicalView Profile

    Indole-3-propionamide (IPAM)

    OtherPreclinical

    IPAM is the market abbreviation for indole-3-propionamide, the amide of indole-3-propionic acid and a close structural relative of melatonin.

    t½ Not established in humans; after intraperitoneal administration of 0.5 mg/kg to one-month-old male Sprague-Dawley rats, brain concentrations were 691 pg indole per mg protein at 2 h, 562 at 4 h and 361 at 8 h, which the authors described as a long half-life relative to melatonin (PMID: 20421998)
    PreclinicalView Profile

    Kisspeptin-10 (KSPTN)

    OtherClinical (investigational)

    KSPTN is the vendor shorthand for kisspeptin, a naturally occurring peptide encoded by the KISS1 gene and the master upstream regulator of the reproductive (hypothalamic-pituitary-gonadal) hormone axis.

    t½ Kisspeptin-10: very short, reported on the order of ~4 minutes (rapid plasma clearance). Kisspeptin-54 is longer-acting (tens of minutes). The brief half-life is why human studies dose it intravenously by bolus or continuous infusion. 20-100 mcg
    PreclinicalView Profile

    Melanotan I

    OtherFDA Approved

    Melanotan I (afamelanotide) is a linear synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) with the substitution of norleucine at position 4 and D-phenylalanine at position 7.

    t½ Controlled-release subcutaneous implant (Scenesse): high inter-subject variability; median Tmax ~36 h, mean Cmax ~3.7 ng/mL, apparent terminal half-life ~15 h, with plasma levels measurable to ~96 h post-dose (FDA pharmacokinetics, n=12). Injected/bolus free peptide: peak plasma at ~1-2 h with an elimination half-life of ~30 minutes; the Nle4/D-Phe7 modifications prolong biological (melanogenic) activity well beyond plasma clearance. 16 mg
    PreclinicalView Profile

    View Full Dosage Guide →

    Protocols, calculator & safety for PNC-27

    Lowest Price per mg

    Ion Peptide logo

    Ion Peptide

    $119.00($11.90/mg)

    Out of stock

    1 vendor · 1 listing

    Research Score

    45

    0 PubMed results

    Quality Indicators

    Data Completeness

    63%
    Description
    Mechanism of Action
    Chemical Data
    Dosing Protocols
    Safety Profile
    PubMed Results
    Interactions
    Vendor Listings

    Quick Facts

    Half-Life

    Unknown (no published PK data)

    Molecular Weight

    4031.8 g/mol

    Administration

    Subcutaneous, Intravenous, Intraperitoneal

    Trial Phase

    Preclinical

    Safety Profile

    Common Side Effects

    • • No human safety data exists
    • • In vitro toxicity against cancer cells only

    Research Disclaimer

    This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

    Frequently Asked Questions

    What is PNC-27 used for in research?

    PNC-27 is a p53-derived peptide that selectively induces membranolysis in cancer cells. It contains the p53 transactivation domain (amino acids 17–26) linked to a membrane-penetrating transmembrane domain (HDM2 binding domain). Uniquely, PNC-27 kills cancer cells by binding to HDM2 protein on the cancer cell membrane surface — where HDM2 (the p53 negative regulator) is aberrantly expressed — creating pores in the cancer cell plasma membrane. Normal cells, which do not express surface HDM2, are spared. This selectivity distinguishes PNC-27 from most cytotoxic compounds. Published research comes primarily from Sarafraz-Yazdi et al. and has demonstrated selective pancreatic cancer, leukemia, and breast cancer cell kill in vitro. PNC-27 remains preclinical with no clinical trials completed.

    What forms does PNC-27 come in?

    PNC-27 is available in vial form.

    How do I compare PNC-27 vendors?

    Compare prices, payment methods, shipping, and COA scores across 1 vendor.

    How many vendors sell PNC-27, and what does it cost per mg?

    1 of the vendors BodyHackGuide tracks list PNC-27 (1 listing). The lowest listed price BodyHackGuide has recorded for PNC-27 is $119.00. No PNC-27 listing recorded as in stock carries a milligram count, so BodyHackGuide states no price per milligram for PNC-27.

    Which vendors have third-party COAs for PNC-27 on file at BodyHackGuide?

    BodyHackGuide holds 5 third-party certificate records for PNC-27, from . No editor has read any of BodyHackGuide's 5 certificate records for PNC-27. The laboratory named on BodyHackGuide's PNC-27 certificate records is Freedom Diagnostics Testing, and the newest test date on them is 6 July 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.

    Research Tools

    Related Compounds

    View All

    Aminotadalafil

    OtherPreclinical

    Aminotadalafil is an unapproved research analog of tadalafil, the PDE5 inhibitor marketed under the brand name Cialis for erectile dysfunction and under Adcirca for pulmonary arterial hypertension.

    2.5 mg - 20 mg (oral)
    9 PubMedView Profile

    B7-33

    OtherPreclinical

    B7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.

    t½ In vitro serum-stability half-life is approximately 6 minutes; B7-33 is rapidly degraded (a lipidated analog extended this to ~60 minutes in the same assay). Human in vivo pharmacokinetics are unpublished, and rapid clearance is expected for a small linear peptide (Praveen et al. 2023, PMID 37047588). 500-4000 mcg subcutaneous per injection (community/self-report research doses; most commonly ~1000 mcg / 1 mg once daily). No validated human dose exists - all figures are empirical extrapolations from rodent pharmacology.
    11 PubMedView Profile

    Diisopropylamine dichloroacetate (DADA)

    OtherApproved (Japan)

    DADA is the abbreviation the research chemical market uses for diisopropylamine dichloroacetate, the diisopropylamine salt of dichloroacetic acid, CAS 660-27-5.

    PreclinicalView Profile

    Indole-3-propionamide (IPAM)

    OtherPreclinical

    IPAM is the market abbreviation for indole-3-propionamide, the amide of indole-3-propionic acid and a close structural relative of melatonin.

    t½ Not established in humans; after intraperitoneal administration of 0.5 mg/kg to one-month-old male Sprague-Dawley rats, brain concentrations were 691 pg indole per mg protein at 2 h, 562 at 4 h and 361 at 8 h, which the authors described as a long half-life relative to melatonin (PMID: 20421998)
    PreclinicalView Profile

    Kisspeptin-10 (KSPTN)

    OtherClinical (investigational)

    KSPTN is the vendor shorthand for kisspeptin, a naturally occurring peptide encoded by the KISS1 gene and the master upstream regulator of the reproductive (hypothalamic-pituitary-gonadal) hormone axis.

    t½ Kisspeptin-10: very short, reported on the order of ~4 minutes (rapid plasma clearance). Kisspeptin-54 is longer-acting (tens of minutes). The brief half-life is why human studies dose it intravenously by bolus or continuous infusion. 20-100 mcg
    PreclinicalView Profile

    Melanotan I

    OtherFDA Approved

    Melanotan I (afamelanotide) is a linear synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) with the substitution of norleucine at position 4 and D-phenylalanine at position 7.

    t½ Controlled-release subcutaneous implant (Scenesse): high inter-subject variability; median Tmax ~36 h, mean Cmax ~3.7 ng/mL, apparent terminal half-life ~15 h, with plasma levels measurable to ~96 h post-dose (FDA pharmacokinetics, n=12). Injected/bolus free peptide: peak plasma at ~1-2 h with an elimination half-life of ~30 minutes; the Nle4/D-Phe7 modifications prolong biological (melanogenic) activity well beyond plasma clearance. 16 mg
    PreclinicalView Profile

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.